Neumora Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• NMRA-335140 · Psychiatry/Neurology
  NMRA-335140 is a selective serotonin 5-HT7 receptor antagonist designed to modulate mood and emotional processing through central nervous system effects.

Phase 1 pipeline

• NMRA-323511

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Neumora Therapeutics, Inc. portfolio CI brief
• Neumora Therapeutics, Inc. pipeline updates RSS